BBIO BridgeBio Pharma, Inc. stock chart & analysis
Conviction 42HealthcareScan · Fri, Nov 6, 2026BridgeBio Pharma, Inc. (BBIO) closed at $74.29 (+0.03%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 60, RS Rating 69, -20.5% from its 52-week high, -2.9% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
BBIO technical analysis
Trend
BBIO's moving averages are mixed — no clean uptrend or downtrend. It closed 6.5% above the 50-day ($69.76) and 2.2% above the 200-day ($72.68). ADX(14) at 31 points to a strong, established trend. It meets 4 of 8 trend-template criteria.
Momentum
RSI(14) is 60, in the bullish half of its range. The MACD histogram is positive. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 69 puts its weighted 12-month performance ahead of about 69% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $210.1M a day on average. ATR(14) is $2.68, 3.6% of price — its typical daily range. On-balance volume is trending up.
Key levels
The chart pattern's support is $63.28 and its resistance $69.66. The 52-week range is $60.55 to $93.42; price is 20.5% below the high and 22.7% above the low. The VWAP anchored at the 52-week high is $75.67, above price.
Performance
BBIO returned -0.9% (1 week), +14.2% (1 month), -12.3% (3 months), +10.2% (6 months), +18.5% (1 year), -2.9% (year to date).
About BridgeBio Pharma, Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Pharmaceutical Preparations · Listed 2019 · 839 employees
Congress activity
Disclosed STOCK Act trades in BBIO · 5 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Gilbert Cisneros house · D · CA · traded 2026-09-29 | Sell | $1K–$15K | 2026-09-29 | 2026-10-12 | |
Gilbert Cisneros house · CA · traded 2026-05-11 | Buy | $1K–$15K | 2026-05-11 | 2026-06-05 | |
Gilbert Cisneros house · CA · traded 2026-03-19 | Buy | $1K–$15K | 2026-03-19 | 2026-04-06 | |
Gilbert Cisneros house · D · CA · traded 2025-09-22 | Buy | $1K–$15K | 2025-09-22 | 2025-10-10 | |
Gilbert Cisneros house · D · CA · traded 2025-08-08 | Buy | $1K–$15K | 2025-08-08 | 2025-09-12 |
Insider activity
SEC Form 4 transactions in BBIO · open-market 10 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Apuli Maricel Chief Accounting Officer · Common Stock · 2026-10-30 | Sell | 2K | $146K | 2026-10-30 | 2026-11-03 |
Kumar Neil Chief Executive Officer · Common Stock · 2026-09-17 | Sell | 8.72K | $602K | 2026-09-17 | 2026-09-21 |
Kumar Neil Chief Executive Officer · Common Stock · 2026-09-17 | Sell | 1.28K | $89K | 2026-09-17 | 2026-09-21 |
Kumar Neil Chief Executive Officer · Common Stock · 2026-08-19 | Sell | 8.1K | $679K | 2026-08-19 | 2026-08-20 |
Kumar Neil Chief Executive Officer · Common Stock · 2026-08-19 | Sell | 1.8K | $152K | 2026-08-19 | 2026-08-20 |
Kumar Neil Chief Executive Officer · Common Stock · 2026-08-19 | Sell | 100 | $9K | 2026-08-19 | 2026-08-20 |
Kumar Neil Chief Executive Officer · Common Stock · 2026-08-18 | Sell | 14.6K | $1.2M | 2026-08-18 | 2026-08-20 |
Kumar Neil Chief Executive Officer · Common Stock · 2026-08-18 | Sell | 17.28K | $1.4M | 2026-08-18 | 2026-08-20 |
Kumar Neil Chief Executive Officer · Common Stock · 2026-08-18 | Sell | 1.2K | $100K | 2026-08-18 | 2026-08-20 |
Kumar Neil Chief Executive Officer · Common Stock · 2026-08-18 | Sell | 1.9K | $154K | 2026-08-18 | 2026-08-20 |
SEC filings
EDGAR filings in BBIO · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.